S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:MRND

IQ U.S. Mid Cap R&D Leaders ETF (MRND) Price, Holdings, & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$23.57
$23.57
50-Day Range
$20.74
$23.57
52-Week Range
$19.08
$23.84
Volume
10 shs
Average Volume
157 shs
Market Capitalization
$4.71 million
Assets Under Management
$4.71 million
Dividend Yield
0.72%
Net Expense Ratio
0.16%

About IQ U.S. Mid Cap R&D Leaders ETF

The IQ U.S. Mid Cap R&D Leaders ETF (MRND) is an exchange-traded fund that is based on the IQ U.S. Mid Cap R&D Leaders index. The fund tracks an index of 100 mid-cap US companies selected and weighted based on the most recently reported one year research and development (R&D) spending. MRND was launched on Feb 8, 2022 and is managed by IndexIQ.

MRND ETF News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive MRND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IQ U.S. Mid Cap R&D Leaders ETF and its competitors with MarketBeat's FREE daily newsletter.

Fund Details

Issuer
IndexIQ
Fund Name
IQ U.S. Mid Cap R&D Leaders ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:MRND
Inception Date
2/8/2022
Fund Manager
Greg Barrato, James Harrison
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
IQ U.S. Mid Cap R&D Leaders Index
Category
Size and Style
Focus
Mid Cap
Development Level
Developed Markets
Region
North America
Number of Holdings
101

Fund Statistics

Assets Under Management
$4.71 million
Average Daily Volume
$0.00
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
The Bank of New York Mellon Corporation
Advisor
IndexIQ Advisors LLC
Custodian
The Bank of New York Mellon Corporation
Distributor
ALPS Distributors, Inc.
Transfer Agent
The Bank of New York Mellon Corporation
Trustee
N/A
Lead Market Maker
GTS

Miscellaneous

Beta
1.09
Creation Fee
$250.00
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

IQ U.S. Mid Cap R&D Leaders ETF Expenses

TypeMRNDMid Cap ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.16%0.34%0.54%0.48%0.51%
Other Expenses0.01%0.36%0.54%0.34%0.58%
Total Expense0.17%0.46%0.70%0.58%0.70%
Fee Waiver-0.01%-0.46%-0.55%-0.22%-0.57%
Net Expense0.16%0.37%0.60%0.54%0.58%

IQ U.S. Mid Cap R&D Leaders ETF (MRND) Holdings


MRND ETF - Frequently Asked Questions

How often does IQ U.S. Mid Cap R&D Leaders ETF pay dividends? What is the dividend yield for IQ U.S. Mid Cap R&D Leaders ETF?

IQ U.S. Mid Cap R&D Leaders ETF declared a dividend on Friday, September 29th. Stockholders of record on Monday, October 2nd will be given a dividend of $0.0341 per share on Thursday, October 5th. The ex-dividend date is Friday, September 29th.
Read our dividend analysis for MRND
.

What does MRND invest in?

IQ U.S. Mid Cap R&D Leaders ETF is a equity fund issued by IndexIQ. MRND focuses on mid cap investments and follows the IQ U.S. Mid Cap R&D Leaders Index. The fund's investments total to approximately $4.71 million assets under management.

What stocks does IQ U.S. Mid Cap R&D Leaders ETF hold?
What is the management fee for IQ U.S. Mid Cap R&D Leaders ETF?

IQ U.S. Mid Cap R&D Leaders ETF's management fee is 0.16% and has other expenses of 0.01%. However, MRND has a fee waiver of -0.01% to reimburse the expenses. The net expense ratio for MRND is 0.16%.

This page (NASDAQ:MRND) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners